SCA Pharmaceuticals
SCA Pharmaceuticals is an FDA 503B outsourcing facility producing sterile admixtures and pre-filled syringes across ~200 NDCs for hospital and healthcare facility pharmacies in the United States, operating two cGMP facilities in Little Rock, AR and Windsor, CT.
- Company typePrivate
- Founded2017
- HeadquartersLittle Rock, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What SCA Pharmaceuticals does
SCA Pharmaceuticals, LLC (dba SCA Pharma) is an FDA 503B outsourcing facility specializing in sterile compounding of injectable pharmaceuticals for hospital and healthcare facility pharmacies. Founded in Little Rock, Arkansas and operating as a privately held company since 2009, SCA Pharma produces sterile admixtures and pre-filled syringes across approximately 200 National Drug Codes in 15 product categories spanning critical care, labor and delivery, anesthesia, and pain management. The company operates two state-of-the-art cGMP-compliant facilities—a 90,000 sq. ft. site in Windsor, Connecticut and a facility in Little Rock, Arkansas—totaling 120,000 sq. ft., and is licensed to operate in 49 states plus Washington, D.C.
Core operations run on Current Good Manufacturing Practice standards under 21 CFR Part 211, FDA 503B GMP guidance, and ICH Q9(R1)/Q10 quality risk and pharmaceutical quality system frameworks. Technology and quality differentiation come from rapid microbiological testing platforms (Celsis ATP bioluminescence validated per USP <1223>, Charles River Endosafe-MCS, Rapid Micro Biosystems Growth Direct), advanced chromatography (HPLC/UPLC), subvisible particulate testing, RFID tagging via Kit Check (the company is the first 503B to apply this across all products and is a DoseID consortium member), and a MasterControl electronic QMS covering training, deviation, CAPA, change control, and supplier audits. An Independent Quality Unit with 90+ quality professionals and 20 licensed pharmacists reports to the CEO. Extended Beyond Use Dating on 69+ products (up to 180 days) reduces hospital drug waste.
SCA Pharma generates revenue through B2B transaction-based sales of compounded sterile products. Go-to-market combines dedicated inside and outside sales teams, a proprietary customer portal (partner.scapharma.com) with recurring-order and new-product-request functionality, a multi-year Vizient GPO agreement reaching over 60% of U.S. healthcare organizations, and since 2025 a Medigi digital procurement platform integration including controlled substances. Distribution is supported by ~5,800 shipments per month nationwide. The company is owned by The Vistria Group and Excellere Partners following a January 2021 acquisition from Enhanced Healthcare Partners.
SCA Pharmaceuticals firmographics
Firmographics- Name
- SCA Pharmaceuticals
- Legal name
- SCA Pharmaceuticals, LLC
- Website
- https://scapharma.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- SCA Pharmaceuticals is an FDA 503B outsourcing facility producing sterile admixtures and pre-filled syringes across ~200 NDCs for hospital and healthcare facility pharmacies in the United States, operating two cGMP facilities in Little Rock, AR and Windsor, CT.
- Ownership category
- akta.pro rank
SCA Pharmaceuticals industry classification
Industry- Product category
- Sterile Compounded Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)
- akta.pro secondary industries
- Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where SCA Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Little Rock
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
SCA Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Sterile Compounding Product Sales: Sale of FDA 503B compliant sterile admixtures and pre-filled syringes to hospital and healthcare facility pharmacies. Products include critical care, labor and delivery, anesthesia, pain management medications, and drug-shortage medications. Revenue generated through direct sales, online portal orders, and channel partner platforms.
- Distribution Platform Sales: Products sold through Medigi digital procurement platform and other purchasing platforms as alternate distribution channels.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
SCA Pharmaceuticals product offering
Product offeringCore offering
SCA Pharmaceuticals is an FDA-registered 503B outsourcing facility that performs cGMP-compliant sterile compounding of ready-to-use medications for hospital and healthcare facility pharmacies. The company manufactures pre-filled syringes, sterile IV admixtures, and other injectable preparations across approximately 200 product NDCs spanning 15 therapeutic categories. Operations run from two state-of-the-art facilities totaling 120,000 sq. ft. in Little Rock, AR and Windsor, CT, with the company licensed in 49 states and Washington D.C.
Product overview
SCA Pharma is a 503B sterile compounding outsourcing facility providing hospital and healthcare facility pharmacies with sterile admixture services and pre-filled syringes. The company operates two state-of-the-art facilities (Little Rock, AR and Windsor, CT) with a portfolio of approximately 200 product NDCs across 15 product categories including critical care, labor and delivery, anesthesia, and pain management medications. Key products include Hydromorphone HCl (various concentrations in IV bags), Sugammadex (pre-filled syringes with up to 120-day BUD), Ketamine HCl, and other analgesics, cardiovascular agents, and anesthetics. The company offers a customer portal for ordering and Buy and Ship Now rapid delivery service.
Differentiator
Problem solved
Functional benefit
Products and services
- Sterile Admixture Services cGMP-compliant sterile compounding and admixture manufacturing service for hospital and healthcare facility pharmacies, producing ready-to-use injectable preparations.
- Pre-filled Syringes Ready-to-administer pre-filled syringes manufactured under cGMP conditions for hospital use, available across multiple therapeutic categories.
- Hydromorphone HCl Sterile compounded Hydromorphone HCl injectable preparation manufactured by SCA Pharma as part of its 503B product catalog.
- Sugammadex Sterile compounded Sugammadex injectable preparation manufactured by SCA Pharma for neuromuscular blockade reversal in hospital settings.
- Ketamine HCl Sterile compounded Ketamine HCl injectable preparation produced for hospital and surgical use.
- Potassium Phosphate Sterile compounded Potassium Phosphate injectable preparation manufactured for electrolyte replacement in hospital pharmacy settings.
- Customer Portal Ordering Service Online ordering and account management platform allowing providers to browse the full SCA catalog, place orders, pay invoices, and track shipments in real time.
- Buy and Ship Now Service Expedited order processing and direct shipment service offered through the SCA customer portal for urgent hospital pharmacy needs.
- Pharmacy Reliability Program SCA's Pharmacy Reliability Program offers hospital pharmacies a stable, contracted supply of ready-to-use compounded sterile preparations, including extended BUD dating on 69+ products to reduce drug waste.
Quantifiable outcome
- Buy & Ship Now orders ship within next business day for orders placed from available inventory
- +3 more outcomes
Companies that use SCA Pharmaceuticals
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
SCA Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature9 records
SCA Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- MedigicoreStrategic partnership expansion providing direct access to controlled substances (CII products) through Medigi platform. Platform integration enables existing Medigi users to seamlessly add SCA Pharma products without retraining on new software systems.
- MedigicoreSCA Pharma expanded distribution of core pharmaceutical products to Medigi digital procurement platform, providing healthcare facilities with additional purchasing options. Medigi integration enables streamlined ordering through existing hospital procurement systems with full product portfolio access including critical CII products.
- VizientcoreMulti-year agreement awarded by Vizient for SCA Pharma's full range of 503B ready-to-use products. Vizient serves over 60% of U.S. health care organizations. Third-party 503B/cGMP assessment confirmed SCA facilities produce high-quality, safe, and efficacious products in compliance with 503B requirements.
- Kit CheckcoreFirst 503B company to use Kit Check's embedded RFID tag on all products for automated medication tracking and safety verification. Enables medication intelligence through radio-frequency identification technology.
- Bausch Advanced TechnologiesminorPartnership during COVID-19 to compound and distribute over 2,500 containers of alcohol-based hand sanitizer at no cost to first responders and front-line healthcare workers in Connecticut.
Scale indicators11 records
Recent moves9 records
Expansion highlights5 records
SCA Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- QuVa Pharma: QuVa is a 503B outsourcing facility providing sterile compounded admixtures and ready-to-use presentations to U.S. hospital pharmacies — the closest direct competitor to SCA in the same regulatory and product category.
- Leiters Health: Leiters is a FDA-registered 503B outsourcing facility producing sterile admixtures, pre-filled syringes, and ophthalmic preparations for hospital and clinical customers — directly comparable in product format and end-market to SCA Pharma.
- Olympia Pharmaceuticals: Olympia is a 503B-registered sterile outsourcing facility producing compounded sterile preparations for hospitals — comparable in regulatory standing, customer base, and product format to SCA.
- Avella Specialty Pharmacy: Avella operates a 503B outsourcing facility producing sterile admixtures and prefilled syringes for hospital customers — overlaps directly with SCA's core product portfolio and hospital-segment focus.
Broad incumbents
- B. Braun Medical (Central Admixture Pharmacy Services): B. Braun's Central Admixture Pharmacy Services (CAPS) is an established 503B sterile compounder serving hospitals nationally — competes directly with SCA but as part of a much larger medical products company.
- Fagron: Fagron is a global leader in pharmaceutical compounding offering APIs, excipients, and compounding services — a broader industry incumbent with overlapping reach into sterile and non-sterile compounding adjacent to SCA's domain.
- Pfizer CentreOne (Contract Manufacturing): Pfizer CentreOne provides contract sterile manufacturing and injectable supply to hospital and 503B-adjacent customers — a much larger incumbent with overlapping capacity and quality standards relevant to SCA's hospital customer base.
- Curia: Curia is a contract development and manufacturing organization with sterile injectable fill-finish capabilities serving pharma and hospital customers — comparable in regulatory depth and sterile manufacturing scale to SCA though broader in scope.
Emerging players
- Stokes Healthcare: Stokes operates a 503B outsourcing facility focused on sterile preparations for hospitals and specialty pharmacies — an emerging player with meaningful product overlap but smaller national reach than SCA.
- Wells Pharma: Wells Pharma operates a 503B-registered sterile compounding outsourcing facility with hospital customers — emerging peer with comparable regulatory profile and product set but more limited national penetration than SCA.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
SCA Pharmaceuticals social profiles
Digital presenceSCA Pharmaceuticals compliance and trust
Trust signalCompliance5 records
SCA Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
SCA Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
SCA Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SCA Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SCA Pharmaceuticals
What does SCA Pharmaceuticals do?
SCA Pharmaceuticals is an FDA-registered 503B outsourcing facility that performs cGMP-compliant sterile compounding of ready-to-use medications for hospital and healthcare facility pharmacies. The company manufactures pre-filled syringes, sterile IV admixtures, and other injectable preparations across approximately 200 product NDCs spanning 15 therapeutic categories. Operations run from two state-of-the-art facilities totaling 120,000 sq. ft. in Little Rock, AR and Windsor, CT, with the company licensed in 49 states and Washington D.C.
Is SCA Pharmaceuticals a public or private company?
SCA Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.
When was SCA Pharmaceuticals founded?
SCA Pharmaceuticals was founded in 2017. It employs 251 to 500 people.
Where is SCA Pharmaceuticals based?
SCA Pharmaceuticals is headquartered in Little Rock, United States, in the North America region.
How does SCA Pharmaceuticals make money?
Two revenue lines are on record. Sterile Compounding Product Sales are the primary driver. The others are distribution Platform Sales.
Who are SCA Pharmaceuticals's main competitors?
Direct peers on record are QuVa Pharma, Leiters Health, Olympia Pharmaceuticals and Avella Specialty Pharmacy. Broad incumbents are B. Braun Medical (Central Admixture Pharmacy Services), Fagron, Pfizer CentreOne (Contract Manufacturing) and Curia. Emerging players are Stokes Healthcare and Wells Pharma.
Does SCA Pharmaceuticals have an API?
No public API is recorded for SCA Pharmaceuticals.
What industry is SCA Pharmaceuticals in?
SCA Pharmaceuticals's product category is Sterile Compounded Pharmaceuticals. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 325412 and its SIC code is 2834.